Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

MicuRx and Cumencor Partner with Pfizer to Develop Antibiotics

publication date: Apr 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
MicuRx Pharmaceuticals, Inc., and Cumencor Pharmaceuticals, Inc. have formed a collaboration with Pfizer. The companies will seek to discover new drugs that treat multi-drug resistant tuberculosis (MDR-TB). Cumencor, a China-based biotech, applies MicuRx's proprietary technology to discover and develop novel antibiotics for MDR-TB. MicuRx, of Union City, CA and Shanghai, develops novel antibiotics to combat infections caused by resistant bacteria. MicuRx presented at the Inaugural ChinaBio® Investor Forum, held in Shanghai in December 2007. More details...

Stock Symbol: (NYSE: PFE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...